Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 12

1.

Baseline visual field findings in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT).

Keltner JL, Johnson CA, Cello KE, Wall M; NORDIC Idiopathic Intracranial Hypertension Study Group.

Invest Ophthalmol Vis Sci. 2014 Apr 29;55(5):3200-7. doi: 10.1167/iovs.14-14243.

PMID:
24781936
[PubMed - indexed for MEDLINE]
2.

Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing-remitting multiple sclerosis.

Winges KM, Werner JS, Harvey DJ, Cello KE, Durbin MK, Balcer LJ, Calabresi PA, Keltner JL.

J Neuroophthalmol. 2013 Dec;33(4):322-9. doi: 10.1097/WNO.0b013e31829c51f7.

PMID:
24051419
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Longitudinal and cross-sectional analyses of visual field progression in participants of the Ocular Hypertension Treatment Study.

Artes PH, Chauhan BC, Keltner JL, Cello KE, Johnson CA, Anderson DR, Gordon MO, Kass MA; Ocular Hypertension Treatment Study Group.

Arch Ophthalmol. 2010 Dec;128(12):1528-32. doi: 10.1001/archophthalmol.2010.292.

PMID:
21149774
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Visual field profile of optic neuritis: a final follow-up report from the optic neuritis treatment trial from baseline through 15 years.

Keltner JL, Johnson CA, Cello KE, Dontchev M, Gal RL, Beck RW; Optic Neuritis Study Group.

Arch Ophthalmol. 2010 Mar;128(3):330-7. doi: 10.1001/archophthalmol.2010.16.

PMID:
20212204
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Visual field quality control in the Ocular Hypertension Treatment Study (OHTS).

Keltner JL, Johnson CA, Cello KE, Bandermann SE, Fan J, Levine RA, Kass MA, Gordon MO; Ocular Hypertension Treatment Study Group.

J Glaucoma. 2007 Dec;16(8):665-9.

PMID:
18091452
[PubMed - indexed for MEDLINE]
6.

Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial.

Optic Neuritis Study Group.

Ophthalmology. 2008 Jun;115(6):1079-1082.e5. Epub 2007 Nov 5.

PMID:
17976727
[PubMed - indexed for MEDLINE]
7.

The association between glaucomatous visual fields and optic nerve head features in the Ocular Hypertension Treatment Study.

Keltner JL, Johnson CA, Anderson DR, Levine RA, Fan J, Cello KE, Quigley HA, Budenz DL, Parrish RK, Kass MA, Gordon MO; Ocular Hypertension Treatment Study Group.

Ophthalmology. 2006 Sep;113(9):1603-12.

PMID:
16949445
[PubMed - indexed for MEDLINE]
8.

Normal visual field test results following glaucomatous visual field end points in the Ocular Hypertension Treatment Study.

Keltner JL, Johnson CA, Levine RA, Fan J, Cello KE, Kass MA, Gordon MO.

Arch Ophthalmol. 2005 Sep;123(9):1201-6.

PMID:
16157799
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Classification of visual field abnormalities in the ocular hypertension treatment study.

Keltner JL, Johnson CA, Cello KE, Edwards MA, Bandermann SE, Kass MA, Gordon MO; Ocular Hypertension Treatment Study Group.

Arch Ophthalmol. 2003 May;121(5):643-50. Erratum in: Arch Ophthalmol. 2008 Apr;126(4):561.

PMID:
12742841
[PubMed - indexed for MEDLINE]
10.

Baseline visual field characteristics in the ocular hypertension treatment study.

Johnson CA, Keltner JL, Cello KE, Edwards M, Kass MA, Gordon MO, Budenz DL, Gaasterland DE, Werner E; Ocular Hypertension Study Group.

Ophthalmology. 2002 Mar;109(3):432-7.

PMID:
11874743
[PubMed - indexed for MEDLINE]
11.

Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study. Ocular Hypertension Treatment Study Group.

Keltner JL, Johnson CA, Quigg JM, Cello KE, Kass MA, Gordon MO.

Arch Ophthalmol. 2000 Sep;118(9):1187-94.

PMID:
10980763
[PubMed - indexed for MEDLINE]
12.

Frequency doubling technology perimetry for detection of glaucomatous visual field loss.

Cello KE, Nelson-Quigg JM, Johnson CA.

Am J Ophthalmol. 2000 Mar;129(3):314-22.

PMID:
10704546
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk